Novartis to collaborate with Alnylam

Thursday 6 January 2022


Novartis is to work with Alnylam Pharmaceuticals Inc on a potential treatment to restore liver function in patients with end-stage liver disease. The three-year research agreement will test potential small interfering RNA (siRNA) therapeutics against a target discovered by Novartis in order to promote the regrowth of functional liver cells. The goal is to provide an alternative to transplantation for patients with liver failure, the Swiss company announced on 9 January.